Policy and Regulatory
Genome UK: shared commitments for UK-wide implementation 2022 to 2025
With initiatives like The 100,000 Genome Project, the UK has led the world on genomic research. In a bid to maintain that position, the governments of all four UK nations have now pledged their support for the sectors’ industry players.
Rare Diseases Action Plan includes focus on technology (England)
The Rare Diseases Action plan from England includes 16 commitments to improve the care of patients, amongst which are digital tools to support faster diagnosis, and new technology that can improve the quality of virtual consultations by enabling patients to see multiple specialists at once.
APAC Value-Based Care Government Roundtable Report from HIMSS
Integrated data collection is vital for value-based healthcare and countries like Taiwan are collecting such data so outcomes between hospitals can be compared and the data can also be used for research purposes.
Optimizations required for DiGA processes (Germany)
Digital apps newly listed in the German reimbursement database recorded strong prescription growth of around 40 percent per month in the first year. In Mar 2022, the first digital apps listed for temporary reimbursement were assessed to meet their coverage with evidence development endpoints and were transited to permanent reimbursement.
Initiatives and companies
Illumina debuts its multi-gene test for cancer in Europe
Gene sequencing specialist Illumina has started rolling out the TruSight Oncology IVD, a new test that looks for a battery of tumour-associated genes from a single tissue sample, and could be used to help guide treatment for a broad range of cancers.
Illumina Accelerator unveils 7 genomics startups selected for latest funding cycle
These include 4SR Biosciences which is exploring new tRNA-based modalities and CRISPR-HR therapeutics which is developing CRISPR technology for rare disease.
AZ expands digital health plans with Huma alliance
AstraZeneca has bought a stake in digital health firm Huma Therapeutics in a deal that will see ownership of AZ’s AMAZE disease management platform transfer to the UK startup.
Japan Is the Next Stop for Guardant’s Liquid Biopsy Test
This follows MHLW granting regulatory approval of the Guardant360 CDx liquid biopsy test as a companion diagnostic for identifying patients with metastatic non-small cell lung cancer (NSCLC) who may benefit from treatment with Lumakras (sotorasib).
Real-time Abbott glucose monitor available to NHS after UK launch
Abbotts FreeStyle Libre 3 is now available via the NHS to eligible people with diabetes in the UK.
The algorithm was able to support medication selection for over 83% of patients, even when two or more medications were used.
Diabetes Tech’s Latest Player Is Debuting April 1
Embecta, Becton Dickinson’s diabetes spinoff will start trading on Nasdaq on April 1.
Researchers want to develop an early warning system for colorectal cancer(Germany)
Researchers in Germany, led by the University of Dresden, want to create an “early warning system” for colorectal cancer using insights from the microbiome.
Scottish hospital pilots AI tech for cervical cancer screening
University Hospital Monklands in Scotland has become the first hospital in the UK, and one of the first in the world, to pilot artificial intelligence technology (the Genius Digital Diagnostics System from Hologic) which could improve early diagnosis of cervical cancer.
Big pharma companies partner to form AI-based start-up
AION Labs comprises four large international pharma companies – AstraZeneca, Merck, Pfizer, and Teva – and another core partner, the Israel Biotech Fund. It is making a global call to optimise of antibody therapeutics using AI technology.
Want to know more about diagnostics? Contact us at info@centivis.com